Stock INSM INSMED INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Insmed Incorporated

Equities

INSM

US4576693075

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
68.98 USD -1.05% Intraday chart for Insmed Incorporated +5.18% +122.59%
06-21 Evercore ISI Boosts Price Target on Insmed to $75 From $42, Maintains Outperform Rating MT
06-20 JPMorgan Raises Insmed's Price Target to $72 From $55, Maintains Overweight Rating MT

Evolution of the average Target Price on Insmed Incorporated

Price target over the last 5 years

History of analyst recommendation changes

ed1e19a32c5849829e0305e97d9a740.Pqtww7QIuVJpM6RgEyreV3VLMIlqXcfiTHbpIAyGjmg.aMQnkYJB9j06feghZh2_BBwJQfArL6KTFS_bblPc6hFO_iGwx3r8ZANxnA~0c3292b670cf59b09d4455ad493c5107

Analyst Recommendations on Insmed Incorporated

Evercore ISI Boosts Price Target on Insmed to $75 From $42, Maintains Outperform Rating MT
JPMorgan Raises Insmed's Price Target to $72 From $55, Maintains Overweight Rating MT
Insmed Insider Sold Shares Worth $1,271,700, According to a Recent SEC Filing MT
Mizuho Adjusts Price Target on Insmed to $82 From $36, Maintains Buy Rating MT
Insmed Insider Sold Shares Worth $3,043,150, According to a Recent SEC Filing MT
UBS Raises Price Target on Insmed to $78 From $58, Maintains Buy Rating MT
Stifel Adjusts Price Target on Insmed to $74 From $67, Maintains Buy Rating MT
Stifel Adjusts Price Target on Insmed to $67 From $39, Maintains Buy Rating MT
Insmed Insider Sold Shares Worth $1,362,075, According to a Recent SEC Filing MT
Insmed Insider Sold Shares Worth $12,064,607, According to a Recent SEC Filing MT
Insmed Insider Sold Shares Worth $6,316,579, According to a Recent SEC Filing MT
Insmed Insider Sold Shares Worth $2,215,081, According to a Recent SEC Filing MT
Wolfe Research Adjusts Price Target on Insmed to $54 From $42, Maintains Outperform Rating MT
Morgan Stanley Adjusts Price Target on Insmed to $60 From $43, Maintains Overweight Rating MT
TD Cowen Adjusts Insmed Price Target to $67 From $45, Maintains Buy Rating MT
Goldman Sachs Adjusts Insmed Price Target to $74 From $49, Maintains Buy Rating MT
BofA Securities Adjusts Price Target on Insmed to $62 From $40, Maintains Buy Rating MT
Wells Fargo Adjusts Insmed Price Target to $77 From $55, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Insmed to $63 From $40, Maintains Overweight Rating MT
JPMorgan Adjusts Price Target on Insmed to $55 From $36, Maintains Overweight Rating MT
UBS Adjusts Insmed Price Target to $58 From $46, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Insmed to $70 From $52, Maintains Buy Rating MT
Truist Securities Adjusts Price Target on Insmed to $68 From $48 After Positive ASPEN Results, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Insmed to $49 From $40, Maintains Buy Rating MT
Mizuho Adjusts Price Target on Insmed to $36 From $35, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
68.98 USD
Average target price
73.44 USD
Spread / Average Target
+6.46%
High Price Target
90 USD
Spread / Highest target
+30.47%
Low Price Target
60 USD
Spread / Lowest Target
-13.02%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Insmed Incorporated

Evercore ISI
JPMorgan Chase
Mizuho Securities
UBS
Stifel Nicolaus
Wells Fargo Securities
Wolfe Research
Morgan Stanley
TD Cowen
Goldman Sachs
BofA Securities
Barclays
HC Wainwright
Truist Securities
Cantor Fitzgerald
Guggenheim
Cowen
Berenberg Bank
SVB Leerink
Credit Suisse

Ratings for Insmed Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. INSM Stock
  4. Consensus Insmed Incorporated